Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ocular manifestations of Graves' disease: a review.

× No keyword cloud information.

44 in total

1. Structure of an exophthalmos-producing factor derived from thyrotropin by partial pepsin digestion.

Authors: L D Kohn; R J Winand
Journal: J Biol Chem Date: 1975-08-25 Impact factor: 5.157

2. Ultrasonographic evidence of a consistent orbital involvement in Graves's disease.

Authors: S C Werner; D J Coleman; L A Franzen
Journal: N Engl J Med Date: 1974-06-27 Impact factor: 91.245

3. Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane.

Authors: J Konishi; M M Herman; J P Kriss
Journal: Endocrinology Date: 1974-08 Impact factor: 4.736

4. Thyrotrophin response to thyrotrophin-releasing hormone in ophthalmic Graves' disease: correlation with other aspects of thyroid function, thyroid suppressibility and activity of eye signs.

Authors: B J Ormston; L Alexander; D C Evered; F Clark; T Bird; D Appleton; R Hall
Journal: Clin Endocrinol (Oxf) Date: 1973-10 Impact factor: 3.478

5. Optic neuropathy of graves's disease. Treatment by transantral or transfrontal orbital decompression.

Authors: C A Gorman; L W DeSanto; C S MacCarty; F C Riley
Journal: N Engl J Med Date: 1974-01-10 Impact factor: 91.245

6. Immunosuppressive therapy for the eye changes of Graves' disease.

Authors: G N Burrow; M S Mitchell; R O Howard; L B Morrow
Journal: J Clin Endocrinol Metab Date: 1970-09 Impact factor: 5.958

7. Radioisotopic thyroidolymphography in patients with Graves' disease.

Authors: J P Kriss
Journal: J Clin Endocrinol Metab Date: 1970-09 Impact factor: 5.958

Review 8. Humoral factors in the pathogenesis of Graves' disease.

Authors: J M McKenzie
Journal: Physiol Rev Date: 1968-01 Impact factor: 37.312

9. Cell-mediated immunity in the exophthalmos of Graves' disease as demonstrated by the migration inhibition factor (MIF) test.

Authors: R E Munro; L Lamki; V V Row; R Volpé
Journal: J Clin Endocrinol Metab Date: 1973-08 Impact factor: 5.958

10. The binding of ( 3 H)thyrotropin and an 3 H-labeled exophthalmogenic factor by plasma membranes of retro-orbital tissue.

Authors: R J Winand; L D Kohn
Journal: Proc Natl Acad Sci U S A Date: 1972-07 Impact factor: 11.205

3 in total

1. Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.

Authors: Tomoaki Higashiyama; Yasuhiro Nishida; Katsutaro Morino; Satoshi Ugi; Yoshihiko Nishio; Hiroshi Maegawa; Masahito Ohji
Journal: Jpn J Ophthalmol Date: 2014-12-03 Impact factor: 2.447

2. Combined irradiation and low-dose cyclophosphamide in the treatment of Graves' ophthalmopathy.

Authors: R Teoh; J Woo
Journal: Postgrad Med J Date: 1987-09 Impact factor: 2.401

3. Acetylcholinesterase antibodies and thyroid autoimmunity.

Authors: A P Weetman; C K Tse; W R Randall; K W Tsim; E A Barnard
Journal: Clin Exp Immunol Date: 1988-01 Impact factor: 4.330

3 in total